First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.

被引：0

作者：

Garmezy, Benjamin

Perez, Cesar Augusto

Kato, Shumei

Sharma, Manish

Quah, Cheng Seok

Tam, Betty

Severson, Paul

机构：

[1] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[2] Florida Canc Specialists, Sarah Cannon Res Inst, Orlando, FL USA

[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA

[4] START Midwest, Grand Rapids, MI USA

[5] Kinnate Biopharma, San Francisco, CA USA

[6] Kinnate Biopharma, San Diego, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS593

引用

页数：1

共 15 条

[1] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
Harding, James J.
Perez, Cesar Augusto
Kato, Shumei
Sharma, Manish
Garmezy, Benjamin
Quah, Cheng Seok
Tam, Betty
Severson, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
[2] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
Harding, J.
Perez, C.
Kato, S.
Sharma, M.
Garmezy, B.
Quah, C.
Tam, B.
Severson, P.
ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
[3] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
Garmezy, B.
Borad, M.
Lin, C. C.
Chen, L. T.
Perez, C. A.
Kato, S.
Tam, B.
Severson, P.
Quah, C. S.
Harding, J. J.
ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
[4] Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).
Goyal, Lipika
Perez, Cesar Augusto
Kato, Shumei
Sharma, Manish
Garmezy, Benjamin
Kobayashi, Ken
Franovic, Aleksandra
Tam, Betty
Voong, Cynthia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
Tyhonas, John S.
Arnold, Lee D.
Cox, Jason M.
Franovic, Aleksandra
Gardiner, Elisabeth
Grandinetti, Kathryn
Kania, Robert
Kanouni, Toufike
Lardy, Matthew
Li, Chun
Martin, Eric S.
Miller, Nichol
Mohan, Adithi
Murphy, Eric A.
Perez, Michelle
Soroceanu, Liliana
Timple, Noel
Uryu, Sean
Womble, Scott
Kaldor, Stephen W.
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1734 - 1746
[6] A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations
Siefker-Radtke, Arlene O.
Mellado, Begona
Decaestecker, Karel
Burke, John M.
O'Hagan, Anne
Avadhani, Anjali Narayan
Zhong, Bob
Santiago-Walker, Ademi E.
De Porre, Peter
Brookman-May, Sabine
Garcia-Donas, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
Iyer, Gopa
Siefker-Radtke, Arlene
Milowsky, Matthew
Shore, Neal
Gao, Xin
Reimers, Melissa A.
Hahn, Noah
Cosman, Rasha
Matsubara, Nobuaki
Necchi, Andrea
Robbrecht, Debbie
Vinceneux, Armelle
Grande, Enrique
Lee, Jae-Lyun
Zhang, Tian
Guren, Tormod
Lauer, Ulrich M.
Sarfaty, Michal
Eigl, Bernhard
Hussain, Syed
Zhao, Xiang
Balar, Arjun V.
Francese, Kaitlyn
Widau, Ryan
Garmezy, Benjamin
CANCER RESEARCH, 2023, 83 (08)
[8] A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)
Zhang, A.
Boni, V.
Hanson, A.
Mantia, C.
Weickhardt, A.
Yu, E.
Gupta, S.
Robert, M.
Iyer, G.
Millward, M.
Morales-Barrera, R.
Hoimes, C.
Berlin, J.
Mittal, K.
Hill, A.
Racca, F.
Pouessel, D.
Lihou, C.
Tran, B.
Loriot, Y.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S15 - S16
[9] A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
Iyer, Gopa
Ebi, Hiromichi
Cook, Natalie
Gao, Xin
Kitano, Shigehisa
Matsubara, Nobuaki
Reimers, Melissa A.
Siefker-Radtke, Arlene O.
Kim, Miso
Galsky, Matthew D.
Robbrecht, Debbie G. J.
Guo, Jun
Eigl, Bernhard J.
Schaverien, Clare
Butts, Brent
Yuen, Eunice
Szymczak, Sylwia
Zhao, Xiang
Widau, Ryan C.
Drakaki, Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[10] A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
Hansen, Aaron Richard
Zhang, Alison Yan
Boni, Valentina
Mantia, Charlene
Yu, Evan Y.
Weickhardt, Andrew James
Robert, Marie
Gupta, Shilpa
Morales-Barrera, Rafael
Hoimes, Christopher J.
Berlin, Jordan
Iyer, Gopa
Millward, Michael
Lihou, Christine Francis
Loriot, Yohan
Pouessel, Damien
Mittal, Kriti
Hill, Andrew Graham
Racca, Fabricio
Tran, Ben
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS904 - TPS904

← 1 2 →